Precision psychiatry, also known as personalized psychiatry or precision medicine in psychiatry, is a cutting-edge approach that aims to tailor psychiatric treatment to individual patients based on their unique characteristics, including genetic makeup, neurobiological markers, and environmental factors. Traditional psychiatric treatments often adopt a one-size-fits-all approach, which may not be effective for all patients and can lead to significant side effects. Precision psychiatry leverages advancements in genetics, neuroimaging, and data analytics to identify biomarkers associated with psychiatric disorders and treatment response. For example, researchers have identified genetic variations that influence an individual's likelihood of responding to certain medications or experiencing adverse effects. By analyzing these genetic markers, clinicians can optimize medication selection and dosages to maximize efficacy and minimize side effects for each patient. Additionally, neuroimaging techniques such as fMRI and EEG provide valuable insights into brain function and connectivity, allowing clinicians to identify neural patterns associated with specific psychiatric symptoms or treatment outcomes. This information can inform treatment decisions and help monitor progress over time. Furthermore, precision psychiatry emphasizes the importance of considering environmental factors such as stress, trauma, and lifestyle habits in understanding psychiatric disorders and designing personalized treatment plans. By taking a holistic approach to patient care, clinicians can address underlying contributors to mental illness and tailor interventions accordingly. Overall, precision psychiatry represents a paradigm shift in psychiatric practice, moving towards more personalized and effective treatments for individuals with mental health conditions. By harnessing the power of genetics, neurobiology, and environmental factors, clinicians can provide targeted interventions that improve outcomes and enhance the overall well-being of patients.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom